EVAX

Evaxion A/SB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.00

+98.7% vs current

Most likely

Base case

45%

Probability

Target price

$3.20

+6.0% vs current

B-

Bear case

30%

Probability

Target price

$1.50

-50.3% vs current

AI sentiment snapshot

Latest data as of 2026-06-18

AI commentary

This remains a cautious monitoring setup, not a high-conviction call. Primary company materials support real 2026 milestones, but independent coverage is thin, there is no usable analyst-revision tape in the packet, and the deterministic prior remains negative with very low evidence quality. The stock is therefore more likely to trade on EVX-01 durability data, EVX-04 execution, and any partnering headlines than on conventional earnings mechanics.

RankAlpha Sentiment Codex - 2026-06-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30eventEVX-01 three-year phase 2 data remains the main binary readoutHigh impact

Evaxion said it completed the one-year extension of the phase 2 EVX-01 study, with last-patient last-visit in April, and expects to present three-year data in the second half of 2026; for a micro-cap biotech with limited commercial revenue, this remains the clearest value-setting catalyst [#PR-2026-05-07].

2026-12-31eventEVX-04 clinical-trial application target in H2 2026High impact

Company materials said EVX-04 preclinical work is intended to support a clinical trial application in the second half of 2026, giving investors a concrete execution checkpoint beyond EVX-01 and a test of whether the platform can advance a second oncology asset toward the clinic [#PR-2026-05-12].

2026-12-31catalystPartnering progress could matter more than quarterly P&LHigh impact

Management said it remains active in several parallel partnership discussions tied to interest in both the platform and pipeline, so any non-dilutive collaboration, licensing, or strategic-development update could matter disproportionately for sentiment and financing risk [#PR-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-18 • Updated nightlySource: Internal modelMethodology